FDA Extends Review Timeline for Abortion Pill Safety Assessment
WHO:
CNN - A three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana’s case regarding the FDA's oversight of mifepristone.
ABC News - Gavin Oxley of Americans United for Life criticized the FDA's timeline as a lack of “true leadership” by Trump administration officials.
ABC News - The Food and Drug Administration (FDA) is conducting the safety review of mifepristone, the main abortion pill.
ABC News - Health Secretary Robert F. Kennedy Jr. ordered the reevaluation of the abortion pill.
ABC News - Gavin Oxley is a representative of Americans United for Life, an anti-abortion group.
WHAT:
CNN - The FDA is using a “statistical data mining method” to discover “unknown safety concerns” related to mifepristone, utilizing data from an electronic database that collects reports of medical injuries and drug side effects.
ABC News - The FDA has repeatedly reaffirmed the safety and effectiveness of mifepristone since its approval in 2000, including easing restrictions on the drug.
ABC News - The FDA's ongoing safety review of mifepristone will continue into next year.
ABC News - The FDA expects to complete a safety study of mifepristone by mid-December this year.
ABC News - A report on the findings of the safety study is expected “no later than March 2027.”
NBC News - A federal judge in Louisiana ordered the FDA to provide an update on its safety study as part of a lawsuit.
WHERE:
ABC News - The FDA is based in Washington, D.C.
NBC News - The lawsuit is being overseen by a federal appeals court in New Orleans, Louisiana.
WHEN:
CNN - The FDA is considering a number of petitions proposing changes to how mifepristone is prescribed and distributed.
ABC News - The FDA expects to complete the safety study by mid-December this year.
ABC News - The report on the findings is expected “no later than March 2027.”
WHY:
CNN - Abortion opponents have focused their efforts on a 2021 decision allowing doctors to prescribe mifepristone online and send it through the mail, which was made permanent under President Biden in 2023.
ABC News - Anti-abortion groups and their allies in Congress have pushed the administration to revisit the use of mifepristone since Trump returned to the White House.
ABC News - Anti-abortion groups and their allies in Congress have pushed the administration to revisit the use of mifepristone in hopes of restricting it.
ABC News - The FDA was directed to provide the latest update by a federal appeals court due to a case brought by the state of Louisiana.
HOW:
CNN - The FDA provided a court-ordered update on its progress in a legal filing late Wednesday.
NBC News - A federal judge in Louisiana ordered the FDA to provide an update on its safety study as part of a lawsuit seeking to overturn a provision allowing mifepristone to be delivered by mail.
ABC News - The FDA provided a court-ordered update on its progress in a legal filing.
(UPDATED October 8, 2026 23:01 UTC)
A three-judge panel for the 5th U.S. Circuit Court of Appeals has raised questions about the merits of Louisiana's case concerning the FDA's oversight of mifepristone. In a recent court filing, the FDA revealed it is using a “statistical data mining method” to uncover potential safety concerns related to the drug, drawing on data from an electronic database that tracks medical injuries and drug side effects. This comes as the FDA is reviewing several petitions that propose changes to how mifepristone is prescribed and distributed, following a 2021 decision that allowed online prescriptions and mail delivery, which was made permanent under Biden in 2023.
--
(UPDATED October 8, 2026 12:01 UTC)
Gavin Oxley of Americans United for Life has criticized the FDA's timeline regarding mifepristone, calling it a sign of “true leadership” lacking from Trump administration officials. The FDA has consistently reaffirmed the safety and effectiveness of mifepristone since its approval in 2000, even easing restrictions on the drug. Meanwhile, a federal judge in Louisiana has ordered the FDA to provide an update on its safety study as part of a lawsuit aimed at overturning a provision that permits mifepristone to be delivered by mail.
--
(UPDATED October 8, 2026 05:05 UTC)
The Food and Drug Administration is currently conducting a safety review of mifepristone, the primary abortion pill, following an order from Health Secretary Robert F. Kennedy Jr. This review is expected to continue into next year, with the FDA aiming to complete a safety study by mid-December and a report on the findings anticipated no later than March 2027. The ongoing scrutiny comes as anti-abortion groups push for a reevaluation of the drug, and a federal judge in Louisiana has mandated the FDA to provide updates as part of a lawsuit.